Evidence map›Paper›PMID 38474337›Full record

ArticleCells2024

Allopurinol Disrupts Purine Metabolism to Increase Damage in Experimental Colitis.

Corey S Worledge, Rachael E Kostelecky, Liheng Zhou, Geetha Bhagavatula, Sean P Colgan, J Scott Lee

Open access · goldAbstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Effects of DietaryMicroorganisms · 2026
    Article
  2. Review
  3. Article
  4. Fecal Microbiota Transplantation Activity ofFoods (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Corey S WorledgeMucosal Inflammation Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Rachael E KosteleckyMucosal Inflammation Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-6529-3831
Liheng ZhouMucosal Inflammation Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Geetha BhagavatulaMucosal Inflammation Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Sean P ColganMucosal Inflammation Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-0431-8887
J Scott LeeMucosal Inflammation Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
University of Colorado Anschutz Medical Campus · US

Funding

DEVELOPMENTAL BIOLOGY TRAINING PROGRAMT32HD007348 · NICHD · UNIVERSITY OF OREGON · PI Chris Q Doe, KRYN STANKUNAS · 1989 to 2026
$6.8M
ROLE OF EPITHELIA IN ISCHEMIA/REPERFUSION INJURYR01DK050189 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 2000 to 2024
$5.0M
Mechanisms of Adenosine ProtectionR01DK095491 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Sean P Colgan · 2012 to 2026
$4.9M
Metabolic Regulation of Inflammation by Microbial SCFAR01DK104713 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Sean P Colgan · 2015 to 2026
$4.7M
METABOLIC CONTROL OF EPITHELIAL AUTOPHAGY DURING INFLAMMATIONR01DK103712 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 2015 to 2019
$1.7M
Microbiota-sourced purines in gut health and diseaseK01DK129410 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LEE, JOSEPH SCOTT · 2021 to 2025
$739k
Metabolic Regulation of Mucosal InflammationI01BX002182 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI COLGAN, SEAN P · 2014 to 2025
–
BLRD Research Career Scientist Award ApplicationIK6BX006475 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI Sean P Colgan · 2024 to 2026
–
BLRD VA I01 BX002182BLRD VA IK6 BX006475NICHD NIH HHS T32 HD007348NIDDK NIH HHS K01 DK129410NIDDK NIH HHS L30 DK133994NIDDK NIH HHS R01 DK050189NIDDK NIH HHS R01 DK095491NIDDK NIH HHS R01 DK103712NIDDK NIH HHS R01 DK104713
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is marked by a state of chronic energy deficiency that limits gut tissue wound healing. This energy shortfall is partially due to microbiota dysbiosis, resulting in the loss of microbiota-derived metabolites, which the epithelium relies on for energy procurement. The role of microbiota-sourced purines, such as hypoxanthine, as substrates salvaged by the colonic epithelium for nucleotide biogenesis and energy balance, has recently been appreciated for homeostasis and wound healing. Allopurinol, a synthetic hypoxanthine isomer commonly prescribed to treat excess uric acid in the blood, inhibits the degradation of hypoxanthine by xanthine oxidase, but also inhibits purine salvage. Although the use of allopurinol is common, studies regarding how allopurinol influences the gastrointestinal tract during colitis are largely nonexistent. In this work, a series of

Indexed as

ColitisInflammatory Bowel DiseasesAllopurinolAnimalsHumansHypoxanthineMicePurinesAllopurinolHypoxanthinePurinesallopurinolcolitisenergy metabolismhypoxanthineinflammatory bowel diseaseproliferationpurineswound healing

Identifiers

PMID38474337
PMCPMC10930830
OpenAlexW4392004685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.